文献速递妇产影像儿科影像US

胎儿室上性快速心律失常产前治疗后的神经发育结局:多中心试验的3年随访

Neurodevelopmental outcome after antenatal therapy for fetal supraventricular tachyarrhythmia: 3-year follow-up of multicenter trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

这项多中心试验的3年随访评估了胎儿室上性心动过速和心房扑动经方案定义的经胎盘治疗后的死亡率和神经发育损害。在45例可分析病例中,死亡率为2.2%(1/45),43例完成神经发育评估的婴儿中神经发育损害发生率为9.3%(4/43)。神经发育损害与诊断时存在胎儿水肿伴皮下水肿及胎儿积液持续时间较长相关。

要点

  • 诊断时心室率中位数在神经发育损害组显著高于无神经发育损害组(265 vs 229 bpm;P=0.003)。
  • 诊断时胎儿水肿伴皮下水肿在神经发育损害组比无神经发育损害组更常见(50.0% vs 2.6%;P=0.019)。
  • 胎儿积液持续时间在神经发育损害组比无神经发育损害组长(中位数10.5 vs 0天;P=0.013)。

核心结论

  • 在无合并症的产前治疗胎儿快速心律失常婴儿中神经发育损害风险低;但在诊断时存在胎儿水肿伴皮下水肿和/或相关严重先天畸形的婴儿中,长期神经学后遗症风险可能有所增加。

研究设计与样本

  • 多中心试验的3年随访研究,原试验纳入50例,1例撤回知情同意、2例胎儿死亡,47例进入随访,2例失访,最终45例可分析;主要终点为校正年龄36个月时的死亡率和神经发育损害。

关键影像表现/征象

  • 诊断时存在胎儿水肿伴皮下水肿在神经发育损害组比无神经发育损害组更常见(50.0% vs 2.6%;P=0.019)。
  • 胎儿积液持续时间在神经发育损害组比无神经发育损害组长(中位数10.5 vs 0天;P=0.013)。
  • 诊断时心室率中位数在神经发育损害组显著高于无神经发育损害组(265 vs 229 bpm;P=0.003)。
  • 脑性瘫痪见于2例早期孕周即有严重皮下水肿或腹水的婴儿。
  • 神经发育延迟见于2例严重先天畸形婴儿(1例结节性硬化症,1例异位综合征)。

诊断标准与关键数值

  • 神经发育损害定义为以下任一结局:脑性瘫痪、双侧失明、双侧耳聋或神经发育延迟。
  • 神经发育延迟采用适宜的发育商量表(主要为京都心理发展量表)或由儿科神经科医师检查评估。
  • 校正年龄36个月时神经发育损害发生率为9.3%(4/43)。
  • 在3例胎儿水肿伴皮下水肿病例中,2例(66.7%)发生神经发育损害。

临床应用与阅片要点

  • 对产前治疗胎儿快速心律失常的婴儿,诊断时存在胎儿水肿伴皮下水肿和/或严重先天畸形者,作者认为长期神经学后遗症风险可能有所增加。
  • 无合并症的产前治疗胎儿快速心律失常婴儿,作者认为神经发育损害风险低。

局限性

  • 2例失访,1例神经发育评估数据缺失。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Although many studies have supported the efficacy of transplacental treatment for fetal supraventricular tachyarrhythmia, the long-term neurodevelopmental outcome after antenatal antiarrhythmic treatment is not well understood. The aim of this study was to investigate the prognosis and neurodevelopmental outcome at 36 months of corrected age and the incidence of tachyarrhythmia after birth, following protocol-defined antenatal therapy for fetal supraventricular tachyarrhythmia.

METHODS: This was a 3-year follow-up study of a multicenter trial that evaluated the efficacy and safety of protocol-defined transplacental treatment for fetal supraventricular tachycardia (SVT) and atrial flutter (AFL). The primary endpoints were mortality and neurodevelopmental impairment (NDI) at 36 months of corrected age. NDI was defined as any of the following outcomes: cerebral palsy, bilateral blindness, bilateral deafness or neurodevelopmental delay. Neurodevelopmental delay was evaluated using appropriate developmental quotient scales, mainly the Kyoto Scale of Psychological Development, or examination by pediatric neurologists. The detection rate of tachyarrhythmia at birth and at 18 and 36 months of corrected age was also evaluated as the secondary endpoint. In addition, the association of NDI at 36 months with perinatal and postnatal factors was analyzed.

RESULTS: Of 50 patients enrolled in the original trial, one withdrew consent and in two there was fetal death, leaving 47 patients available for enrollment in this follow-up study. Of these, 45 cases were available for analysis after two infants were lost to follow-up. The mortality rate was 2.2% (1/45) during a median follow-up of 3.2 (range, 2.1-9.4) years. The infant died at the age of 2.1 years. Another infant had missing neurodevelopmental assessment data. In the remaining 43 infants, at 36 months of corrected age, NDI was detected in 9.3% (4/43) overall and in two of three (66.7%) cases with fetal hydrops with subcutaneous edema. Cerebral palsy was noted in two infants with severe subcutaneous edema or ascites at an early gestational age. Neurodevelopmental delay was found in two infants with severe congenital abnormalities (one with tuberous sclerosis and the other with heterotaxy syndrome). Tachyarrhythmia was present in 31.9% (15/47) cases in the neonatal period and decreased to 8.9% (4/45) and 4.5% (2/44) at 18 and 36 months of corrected age, respectively. The median ventricular rate at diagnosis was significantly higher in infants with NDI compared to those without (265 vs 229 bpm; P = 0.003). In infants with NDI, compared to those without, fetal hydrops with subcutaneous edema at diagnosis was more common (50.0% vs 2.6%; P = 0.019) and the duration of fetal effusion was longer (median, 10.5 vs 0 days; P = 0.013). Postnatal arrhythmia and physical development abnormalities were not associated with NDI.

CONCLUSIONS: This multicenter 3-year follow-up study is the first to demonstrate the long-term mortality and morbidity of infants born following protocol-defined transplacental treatment for fetal SVT and AFL. NDI was associated with the presence of fetal hydrops with subcutaneous edema at diagnosis and longer duration of fetal effusion. Neurodevelopmental delay was detected only in infants with severe congenital abnormalities. Therefore, in infants that have undergone antenatal treatment for fetal tachyarrhythmia and in which there are no comorbidities, the risk of NDI is low. However, in those with fetal hydrops with subcutaneous edema and/or associated severe congenital abnormalities, the risk for long-term neurologic morbidity might be considered somewhat increased. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Miyoshi T, Maeno Y, Matsuda T, et al. Neurodevelopmental outcome after antenatal therapy for fetal supraventricular tachyarrhythmia: 3-year follow-up of multicenter trial. Ultrasound Obstet Gynecol. 2023. PMID: 36350016. doi:10.1002/uog.26113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。